|
Fourth Quarter and Full Year Results 2007 |
|
|
|
31 Jan 2008 |
|
Sales for the full year increased 7 percent to $29,559 million. The inclusion of MedImmune for seven months increased sales by 3 percent. Excluding US sales of Toprol-XL™ from the current and the prior year, sales increased 10 percent
LONDON, UK | January 31, 2008 | Download AstraZeneca fourth quarter results and full year results 2007
-Press Release
-Figures
|
